Best Nootropic Peptides: Semax, Selank, Cerebrolysin, P21 and Dihexa

Nootropic peptides are short chains of amino acids, or drugs built from them, that are claimed to sharpen memory, focus or mood. The best known, Semax and Selank, were developed in Russia and are sold there as nasal-drop medicines. Others, such as P21 and Dihexa, have only ever been tested in rodents and cell cultures.

This guide covers the six compounds most often sold under the name: Semax, Selank, Noopept, P21, Cerebrolysin and Dihexa. For each one: what it is, what human and animal studies show, the doses used in studies or commonly reported, and the known risks. It also explains why GHK-Cu and Epitalon do not belong on these lists.

The short version: none is FDA-approved, the human evidence ranges from modest to non-existent, and none has been shown in good trials to make a healthy person think better.

What Are Nootropic Peptides?

A peptide is a short chain of amino acids; a nootropic is a substance claimed to improve cognitive function. “Nootropic peptide” is a marketing category rather than a scientific class: the compounds sold under the name have different origins, targets and levels of evidence.

Most are modified versions of signaling molecules the body already makes: Semax is built from a fragment of ACTH, Selank from the immune peptide tuftsin, P21 from the growth factor CNTF, and Dihexa from angiotensin IV.

A Short History

The word “nootropic” was coined in 1972 by Corneliu Giurgea, whose team at the Belgian company UCB had made piracetam in 1964. Peptide nootropics came later and mostly from Moscow: Semax and Selank from the Institute of Molecular Genetics, Noopept from the Zakusov Institute of Pharmacology. Cerebrolysin comes from an Austrian company, while P21 and Dihexa came out of US research labs looking for Alzheimer’s treatments.

How They Are Thought to Work

Several of these compounds raise brain-derived neurotrophic factor (BDNF), a protein that supports the growth and survival of neurons, in animal studies. Others act on anxiety-related signaling or on growth-factor receptors that help form new synapses. These mechanisms come almost entirely from rodent and cell studies.

Peptides are broken down quickly in the gut and blood, and few cross the blood-brain barrier. That is why Semax and Selank are given as nasal drops, Cerebrolysin is injected, and P21 and Dihexa were chemically modified to survive longer.

Nootropic Peptides at a Glance

1. Semax

Semax is a seven-amino-acid peptide (Met-Glu-His-Phe-Pro-Gly-Pro). The first four amino acids are a fragment of ACTH, the pituitary hormone that drives cortisol release; the Pro-Gly-Pro tail was added to slow its breakdown. Semax affects attention and learning in animals without acting as a hormone.

In Russia, Semax is a registered nasal-drop medicine: a 0.1% strength for cognitive and nervous-system conditions and a 1% strength for stroke care. It is not approved in the US or the EU.

What the Research Shows

• Animal data: in rats, a nasal dose raised BDNF and its receptor TrkB in the hippocampus, a brain region central to memory, and Semax improved learning in some tasks. Rat stroke models suggest effects on inflammation and blood vessel genes.
• Human data: mostly small Russian clinical studies in ischemic stroke and cognitive disorders, often with limited blinding and published mainly in Russian journals. Large independent trials do not exist.
• Healthy people: there are no good controlled trials. Claims about ADHD and depression come from animal models and small reports.

Research vendors also sell N-Acetyl Semax Amidate, a modified version said to be stronger and longer-lasting. There are no published human studies of this form, so those claims are unverified.

Doses and Side Effects

The Russian 0.1% drops contain 1 mg of Semax per mL. Commonly reported doses range from a few hundred micrograms to about 1 mg a day, split into two or three nasal doses; these are reported doses, not tested recommendations. Reported side effects are usually mild (nasal irritation, headache), and long-term safety data in healthy users are lacking.

2. Selank

Selank is also seven amino acids long (Thr-Lys-Pro-Arg-Pro-Gly-Pro): the natural immune peptide tuftsin with the same Pro-Gly-Pro tail as Semax. It was developed by the same Moscow institute, together with the Zakusov Institute of Pharmacology, and is registered in Russia as an anti-anxiety nasal drop.

Animal and cell studies suggest Selank acts on the brain’s GABA system, the system benzodiazepines target, but through a different route. It also appears to slow the breakdown of enkephalins, the body’s own opioid peptides, and to change immune signaling.

What the Research Shows

Small Russian trials in patients with generalized anxiety disorder and neurasthenia reported that Selank reduced anxiety about as much as the benzodiazepine medazepam, with less sedation. These trials were small and have not been repeated by independent groups. Evidence for better memory or focus comes mostly from animal models, and the N-Acetyl Selank Amidate version sold online has no published human research. For a direct comparison of the two Russian peptides, see Semax vs Selank.

Doses and Side Effects

Commonly reported intranasal doses are 250-500 mcg a day. Reported side effects include nasal irritation and tiredness. The Russian studies did not report dependence or withdrawal, but the safety data are limited to small, short studies.

3. Noopept

Noopept (omberacetam) is N-phenylacetyl-L-prolylglycine ethyl ester, a dipeptide-based drug developed at the Zakusov Institute in Moscow in the 1990s. It is often grouped with the racetams because it was designed with piracetam as a model, but it is a modified dipeptide that the body converts into cycloprolylglycine, a cyclic dipeptide found naturally in the brain. It is the only compound here taken by mouth.

The claim that Noopept is “1,000 times more potent than piracetam” refers to the dose used in rodent studies (milligrams, not grams), not to a bigger effect.

What the Research Shows

• Animal data: Noopept raised NGF and BDNF, two growth factors for neurons, in the rat hippocampus and protected brain cells in injury models.
• Human data: a Russian study in patients with mild cognitive impairment after vascular disease or brain injury compared Noopept with piracetam and reported similar improvements on cognitive scales. The study was small and has not been independently replicated.

Doses and Side Effects

The Russian clinical studies used 10 mg twice a day; commonly reported doses are 10-30 mg a day in two or three doses. Reported side effects include headache, irritability and trouble sleeping, mostly at higher doses. It is not approved in the US, where it is sold online as a supplement or research chemical.

4. P21 (P021)

P21 is a small synthetic peptide-like molecule developed at the New York State Institute for Basic Research in Developmental Disabilities. It is built from an active region of ciliary neurotrophic factor (CNTF), a growth factor for nerve cells, with an adamantane group added so that it lasts longer and reaches the brain.

What the Research Shows

In mice and rats, P21 increased the formation of new neurons in the hippocampus, raised BDNF and improved memory tests. In mouse models of Alzheimer’s disease it reduced tau pathology and slowed memory loss. No human trial has been published, so the claim that P21 improves cognition in people with age-related decline is not true.

Doses and Risks

With no human studies, there is no studied human dose: injectable doses passed around on forums are guesswork, and the purity of research-vendor P21 is rarely verified. Its long-term effects on growth-factor signaling are unknown.

5. Cerebrolysin

Cerebrolysin is not a single peptide but a mixture of small peptides and free amino acids made from purified pig brain proteins by EVER Pharma in Austria. It is a prescription drug in a number of countries in Europe, Asia and the former Soviet Union for stroke, traumatic brain injury and dementia. It is not approved in the US.

It is given only by injection: in clinical trials, usually as a daily intravenous infusion in courses lasting a few weeks; smaller volumes can be injected into muscle.

What the Research Shows

• Stroke: Cochrane reviews of acute ischemic stroke trials found no benefit on death and no reliable evidence of better recovery.
• Dementia: a Cochrane review in vascular dementia found possible benefits on cognition, but from few trials at risk of bias, and did not recommend routine use. Some Alzheimer’s trials were positive, several of them funded by the manufacturer.
• Healthy people: there is no good evidence that Cerebrolysin improves cognition in healthy individuals.

Side Effects and Risks

Reported side effects include dizziness, headache, sweating, agitation and injection-site reactions, and the label lists epilepsy and severe kidney disease as reasons not to use it. As an animal-derived injectable, grey-market ampoules carry a real risk of counterfeits and contamination.

6. Dihexa

Dihexa (PNB-0408) is a modified fragment of angiotensin IV developed at Washington State University. It binds hepatocyte growth factor (HGF) and boosts signaling through HGF’s receptor, c-Met, which promotes the formation of new synapses in lab studies.

What the Research Shows

In rats, Dihexa improved performance in a water maze test, both in animals given scopolamine to impair memory and in aged animals. The often-repeated claim that it is “ten million times more potent than BDNF” comes from a cell-culture measure of synapse formation in the same research, not from any effect on memory in people. No human trial of Dihexa has been published.

In 2021 the founding chief executive of Athira Pharma, the company built on this research, resigned after an internal investigation found she had altered images in papers from her doctoral work. A related HGF/MET drug from the same research line, fosgonimeton, later failed to beat placebo on its main outcome in Alzheimer’s trials.

Risks

The HGF/c-Met pathway also drives the growth and spread of several cancers. Long-term stimulation of it raises a theoretical cancer concern that has never been studied in humans. With no human dose data and no safety data, any dose of Dihexa is an experiment.

Often Listed, But Not Nootropics: GHK-Cu and Epitalon

GHK-Cu is a copper-binding tripeptide found in human blood. Its evidence is in skin and wound healing, mainly from creams and lab studies. There is no evidence that it improves memory or focus, and a skin cream would not deliver meaningful amounts to the brain. Lists that rank GHK-Cu cream as a nootropic with “no side effects” are simply wrong.

Epitalon is a four-amino-acid peptide (Ala-Glu-Asp-Gly) modeled on a pineal gland extract by Vladimir Khavinson’s group in St. Petersburg, and studied mostly by that group for telomerase activity and melatonin rhythms in cells and animals. It is an anti-aging research peptide, not a cognitive enhancer; there are no human trials on memory or focus.

Do Nootropic Peptides Work in Healthy People?

Almost all of the human research on these compounds is in patients with stroke, brain injury, dementia or anxiety disorders. Effects in an injured or ageing brain do not predict effects in a healthy one. No large, independent, placebo-controlled trial shows that any of these compounds improves memory or focus in healthy adults.

User reports of sharper focus on Semax or calmer mood on Selank may be genuine, but they are subjective and open to placebo effects. For brain fog, good sleep, regular exercise and checking for treatable causes such as anxiety, depression or thyroid problems have far stronger evidence than any peptide.

Safety, Legal Status and Product Quality

In the US none of these compounds is FDA-approved. Semax, Selank, P21 and Dihexa are sold online as research chemicals “not for human consumption”, so no regulator checks what is in the vial: purity, the real dose and sterility all depend on the seller. Anyone buying a research peptide should ask for a third-party certificate of analysis and know how to read a peptide COA.

SwissChems Contents6 sections01What Is SwissChems?02Product Range03Top 3 Featured Products04Why It Gets Attention From Fitness Researchers05Testing, Documentation & Regulatory History06Frequently Asked Questions SwissChems is an online research-compound supplier covering SARMs,…

9.2Excellent

Visit SwissChemsBRAWN1010% OFFCopy

Pros

• Exceptional purity & testing (≥98%)
• Pharmaceutical-style packaging for stability
• Broad catalog across peptides & nootropics
• Strong reputation & consistency across years

Cons

• Some items frequently out of stock due to high demand
• Limited long-term data for some compounds

Groups who should avoid these compounds include:

• Anyone pregnant or breastfeeding, and anyone under 18
• People with epilepsy or a history of seizures
• People with a current or past cancer (especially with Dihexa and P21)
• People on psychiatric medication, sedatives or anticonvulsants, unless a doctor is involved

There are no studies of these compounds taken together, so combining them adds unknowns without any evidence of extra benefit.